TMEM97 and cancer: Concerning clinical candidatestargeting the σ2R subtype, two different antagonists,roluperidone and CT1812 (Figure 3), entered phaseII and phase I clinical trials to establish their efficacy and safetyin the treatment of schizophrenia and Alzheimer’s disease,respectively.67,68 Interestingly, none of the σRligands with intrinsic cytotoxicity properties discovered so far arein clinical trials to treat cancer, likely due to the inconsistentdata concerning the efficacy of σRs ligands on preclinical in vivo models.